Upfront Autologous HSCT vs Carfilzomib–Cyclophosphamide–Dexamethasone Consolidation With Carfilzomib Maintenance for Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial
Lancet Haematol 2022 Dec 15;[EPub Ahead of Print], K Yong, W Wilson, RM de Tute, M Camilleri, K Ramasamy, M Streetly, J Sive, CA Bygrave, R Benjamin, M Chapman, SJ Chavda, EH Phillips, M Del Mar Cuadrado, G Pang, R Jenner, T Dadaga, S Kamora, J Cavenagh, L Clifton-Hadley, RG Owen, R PopatFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.